Free Trial

Eton Pharmaceuticals Q2 2024 Earnings Report

Eton Pharmaceuticals logo
$14.49 +0.10 (+0.72%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eton Pharmaceuticals EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Eton Pharmaceuticals Revenue Results

Actual Revenue
$9.07 million
Expected Revenue
$10.00 million
Beat/Miss
Missed by -$930.00 thousand
YoY Revenue Growth
N/A

Eton Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Eton Pharmaceuticals Earnings Headlines

Eton secures US patent for diabetes insipidus treatment
Trump doesn’t give a damn
Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…
Eton Pharmaceuticals granted new patent from USPTO
Craig-Hallum Reaffirms Their Buy Rating on Eton Pharmaceuticals (ETON)
See More Eton Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email.

About Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON), a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

View Eton Pharmaceuticals Profile

More Earnings Resources from MarketBeat